Reproductive Health

  • MENOPUR®
    MENOPUR®

    (highly purified human menopausal gonadotrophin)

    Fertility
  • MENOPUR® (highly purified human menopausal gonadotrophin)

    MENOPUR (HP-hMG) is a highly purified human menopausal gonadotrophin containing a 1:1 ratio of FSH (follicle stimulating hormone) and LH (luteinizing hormone) bioactivity.

     

     MENOPUR has indications for treatment of female and male infertility in the following groups of patients:

     

     Female:
    • Anovulatory women: MENOPUR can be used to stimulate follicle development in amenorrhoeic patients.
    • Women undergoing superovulation within a medically assisted fertilisation programme: MENOPUR can be used to induce multiple follicular development in patients undergoing an assisted conception technique such as in-vitro fertilisation (IVF).
    Male:
    • Hypogonadotrophic hypogonadism in men.
    Find out more at www.menopur.co.uk

     

    For specific product information please consult the summary of product characteristics (SPCs): 
    Menopur 75 IU  
    Menopur 150 IU 
    Menopur 600 IU 
    Menopur 1200 IU 
     

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only. 

     

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

  • LUTIGEST®
    LUTIGEST®

    (progesterone)

    Fertility
  • LUTIGEST® (progesterone)

    LUTIGEST®  (progesterone) is a vaginal tablet containing 100 mg progesterone per tablet. Lutigest is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment programme for infertile women.

     

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor. All information on this site is intended for UK audiences only. For specific product information please consult the summary of product characteristics (SPC) at https://www.medicines.org.uk/emc/medicine/29749

     

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.g

  • MYSODELLE®
    MYSODELLE®

    (misoprostol vaginal insert)

    Obstetrics
  • MYSODELLE® (misoprostol vaginal insert)

    MYSODELLE® (misoprostol vaginal insert) is a prostaglandin E1 treatment used to help the start of the birth process from 36 weeks of pregnancy in women with an unfavourable cervix.

     

    MYSODELLE® is administered through a controlled release vaginal insert contained in a polyester pouch with a withdrawal tape. MYSODELLE® releases misoprostol at a constant and controlled rate. MYSODELLE® can easily be pulled out by the doctor or midwife when it is time to remove it.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor.All information on this site is intended for UK audiences only. For specific product information please consult the summary of product characteristics (SPC) https://www.medicines.org.uk/emc/medicine/29434

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

    RG/1275/2015/UK

     

  • PROPESS®
    PROPESS®

    (dinoprostone vaginal insert)

    Obstetrics
  • PROPESS® (dinoprostone vaginal insert)

    PROPESS® is a controlled-release vaginal insert containing dinoprostone. It is used to help ripen the cervix which is necessary to allow doctors to start the labour process artificially when there is a clinical needed.

    PROPESS® is administered through a controlled-release vaginal insert contained in a polyester pouch with a withdrawal tape. It releases dinoprostone at a constant and controlled rate. PROPESS® can easily be pulled out by the doctor or midwife when it is time to remove it.

     

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor.All information on this site is intended for UK audiences only. For specific product information please consult the summary of product characteristics (SPC) www.medicines.org.uk/EMC/medicine/16898 .

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

  • PABAL®
    PABAL®

    (carbetocin)

    Obstetrics
  • PABAL® (carbetocin)

    PABAL®  (carbetocin) is a long-acting, oxytocin analogue that is used to prevent bleeding in women who have had a baby by caesarean section.

    In some women, after a caesarean section, the uterus (womb) does not contract quickly enough. This makes it more likely that they will bleed more than normal. Pabal makes the uterus contract and so reduces the risk of bleeding.

    PABAL® is administered via a single intravenous injection before or after the delivery of the placenta.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor.All information on this site is intended for UK audiences only. For specific product information please consult the summary of product characteristics (SPC) https://www.medicines.org.uk/emc/medicine/17274

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

  • TRACTOCILE®
    TRACTOCILE®

    (atosiban)

    Obstetrics
  • TRACTOCILE® (atosiban)

    TRACTOCILE® (atosiban) is a treatment indicated to delay imminent pre-term birth of the baby between 24 and 33 weeks of gestation, which is the main cause of death and disability in new-born infants. The active ingredient, atosiban, is an oxytocin/vasopressin antagonist that blocks the action of a normal hormone in the body called oxytocin and is able to prevent uterine contractions and relax the uterus, such medicine is called a tocolytic.

    TRACTOCILE®  is administered by an intravenous infusion in three successive stages to delay imminent pre-term birth.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advice on medical issues please consult your doctor.All information on this site is intended for UK audiences only. For specific product information please consult the summary of product characteristics (SPC) https://www.medicines.org.uk/emc/medicine/4297

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

UK office

Ferring Pharmaceuticals Ltd.
Drayton Hall, Church Road, West Drayton.
UB7 7PS

Telephone : +44(0)8449310050

Contact

Global Locator

Corporate Global Locator

You are now leaving www.Ferring.co.uk , a website of Ferring Pharmaceuticals Ltd UK. Links to all outside websites are provided as a resource to our visitors. Ferring Pharmaceuticals Ltd accepts no responsibility for the content of other websites.